249 related articles for article (PubMed ID: 31160638)
81. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E
Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579
[No Abstract] [Full Text] [Related]
82. [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Huang YQ; Zhang XY; Wu SX; Guo XZ; Pan JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1641-1646. PubMed ID: 29262890
[TBL] [Abstract][Full Text] [Related]
83. Recurrent transcriptional responses in AML and MDS patients treated with decitabine.
Upadhyay P; Beales J; Shah NM; Gruszczynska A; Miller CA; Petti AA; Ramakrishnan SM; Link DC; Ley TJ; Welch JS
Exp Hematol; 2022 Jul; 111():50-65. PubMed ID: 35429619
[TBL] [Abstract][Full Text] [Related]
84. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T; Furstoss N; Savy C; El Manaa W; Zerhouni M; Blot L; Calleja A; Dufies M; Dubois A; Ginet C; Mounier N; Garnier G; Raynaud S; Rohrlich PS; Peterlin P; Stamatoullas A; Chermat F; Fenaux P; Jacquel A; Robert G; Auberger P
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881723
[TBL] [Abstract][Full Text] [Related]
85. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract][Full Text] [Related]
86. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.
Ng KP; Ebrahem Q; Negrotto S; Mahfouz RZ; Link KA; Hu Z; Gu X; Advani A; Kalaycio M; Sobecks R; Sekeres M; Copelan E; Radivoyevitch T; Maciejewski J; Mulloy JC; Saunthararajah Y
Leukemia; 2011 Nov; 25(11):1739-50. PubMed ID: 21701495
[TBL] [Abstract][Full Text] [Related]
87. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
88. Evolving strategies in the treatment of MDS and AML.
Stone R; Sekeres M; Garcia-Manero G
Clin Adv Hematol Oncol; 2009 Aug; 7(8):1-14; quiz 2 p following 14. PubMed ID: 19927982
[TBL] [Abstract][Full Text] [Related]
89. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
90. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
91. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
92. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
93. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
[No Abstract] [Full Text] [Related]
94. Decitabine Induces Gene Derepression on Monosomic Chromosomes:
Greve G; Schüler J; Grüning BA; Berberich B; Stomper J; Zimmer D; Gutenkunst L; Bönisch U; Meier R; Blagitko-Dorfs N; Grishina O; Pfeifer D; Weichenhan D; Plass C; Lübbert M
Cancer Res; 2021 Feb; 81(4):834-846. PubMed ID: 33203699
[TBL] [Abstract][Full Text] [Related]
95. Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia.
Zhou H; Zhang Q; Huang W; He C; Zhou C; Zhou J; Ning Y
Int J Oncol; 2023 May; 62(5):. PubMed ID: 37052262
[TBL] [Abstract][Full Text] [Related]
96. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Liberante FG; Pouryahya T; McMullin MF; Zhang SD; Mills KI
Oncotarget; 2016 Feb; 7(6):6609-19. PubMed ID: 26735888
[TBL] [Abstract][Full Text] [Related]
97. Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.
Chilakala S; Feng Y; Li L; Mahfouz R; Quteba E; Saunthararajah Y; Xu Y
Sci Rep; 2019 Mar; 9(1):4558. PubMed ID: 30872721
[TBL] [Abstract][Full Text] [Related]
98. [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Zhou J; Wang J; Liu H; Zheng H; Ma L; Wang P; Yan S; Wu D; Fu C; Qiu H; Tang X; Jin Z; Han Y; Miao M
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(12):920-4. PubMed ID: 26081055
[TBL] [Abstract][Full Text] [Related]
99. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
[TBL] [Abstract][Full Text] [Related]
100. Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow.
Tamura S; Kanamaru A; Takemoto Y; Kakishita E; Nagai K
Br J Haematol; 1993 Jun; 84(2):219-26. PubMed ID: 8398821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
